Purpose: A surge in the use of semaglutide injection (Ozempic) approved to treat type 2 diabetes (T2D) has led to a global supply shortage. We investigated contemporary user rates and clinical characteristics of semaglutide (Ozempic) users in Denmark, and the extent of "off-label" prescribing for weight loss.
Patients And Methods: Nationwide population-based cross-sectional study based on linked health registries January 2018 through December 2023. All adults who received a first prescription of semaglutide once weekly (Ozempic) were included. We examined quarterly rates of new users and total user prevalences, using other glucagon-like peptide-1 receptor agonists and weight loss medications as comparison. We also investigated user characteristics including T2D, glucose control, comedications, and cardiorenal disease.
Results: The new user rate of semaglutide (Ozempic) remained stable at approximately 4 per 1000 adult person-years between 2019 and 2021 and then accelerated, peaking at 10 per 1000 in the first quarter of 2023 after which it declined sharply. User prevalence increased to 91,626 users in Denmark in 2023. The proportion of semaglutide (Ozempic) new users who had a record of T2D declined from 99% in 2018 to only 67% in 2022, increasing again to 87% in 2023. Among people with T2D who initiated semaglutide (Ozempic) in 2023, 52% received antidiabetic polytherapy before initiation, 39% monotherapy, and 8% no antidiabetic therapy. Most T2D initiators had suboptimal glucose control, with 83% having an HbA1c ≥48 mmol/mol and 68% ≥53 mmol/mol despite use of antidiabetic medication, and 29% had established atherosclerotic cardiovascular disease or kidney disease.
Conclusion: The use of semaglutide (Ozempic) in Denmark has increased dramatically. Although not approved for weight loss without T2D, one-third of new users in 2022 did not have T2D. Conversely, most initiators with T2D had a clear medical indication for treatment intensification, and "off-label" use can only explain a minor part of the supply shortage.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11057509 | PMC |
| http://dx.doi.org/10.2147/CLEP.S456170 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Fasting on Physical Activity Motivation and Weight Reduction in Patients Administered Glucagon-Like Peptide-1 Agonists: A Qualitative Study.
Patient Prefer Adherence
January 2025
College of Medicine, King Faisal University, Al Hofuf, Saudi Arabia.
Purpose: This study aims to investigate the possible impacts of fasting on physical activity and weight loss in adult users of glucagon-like peptide-1 (GLP-1) agonists, specifically semaglutide and tirzepatide, using qualitative methods to gain in-depth insights into participants' experiences and perceptions.
Patients And Methods: A qualitative study was conducted at the Polyclinic at King Faisal University, Al-Ahsa, Saudi Arabia, during and after Ramadan in 2024, along with the completion of International Physical Activity Questionnaires (IPAQs). The semi-structured interviews and the IPAQ were used to assess physical activity levels.
Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review.
J Clin Transl Endocrinol
December 2024
Division of Endocrinology Diabetes and Metabolism, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Cystic fibrosis-related diabetes (CFRD) is the most common non-pulmonary comorbidity in people with cystic fibrosis (CF). Current guidelines recommend insulin therapy as the treatment of choice for people with CFRD. In the past, obesity and overweight were uncommon in individuals with CF.
View Article and Find Full Text PDFCorrigendum to "Safety and efficacy of semaglutide in post kidney transplants patients with type 2 diabetes or post-transplant diabetes" [J. Clin. Translat. Endoc. 36C (2024) 100343].
J Clin Transl Endocrinol
December 2024
College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh 22490, Saudi Arabia.
[This corrects the article DOI: 10.1016/j.jcte.
View Article and Find Full Text PDF12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.
EClinicalMedicine
August 2024
Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, United Kingdom.
Background: While semaglutide, approved for type-2 diabetes mellitus (T2DM), is being investigated as a treatment for brain disorders, concerns over adverse neuropsychiatric events have emerged. More data are therefore needed to assess the effects of semaglutide on brain health. This study provides robust estimates of the risk of neurological and psychiatric outcomes following semaglutide use compared to three other antidiabetic medications.
View Article and Find Full Text PDFPrediabetes and diabetes mellitus type II after ischemic stroke.
Eur Stroke J
January 2025
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Introduction: The progression of diabetes status in post-stroke patients remains under-investigated, particularly regarding new treatments for type II diabetes mellitus (DM II), like glucagon-like peptide 1 receptor agonists (GLP-1-RA) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors, which have not been studied in the post-stroke setting.
Patients And Methods: Eight hundred eighty-four consecutive ischemic stroke patients recruited to our prospective STROKE-CARD Registry were assessed concerning their glycemic status at baseline (normoglycemia, prediabetes, DM II) and change over time within 1 year follow-up. Multivariate logistic regression was performed to identify factors associated with transitioning from normoglycemia to prediabetes or DM II.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!